Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Venous thromboembolism (VTE) poses a major clinical concern due to its life-threatening nature, and obese and morbidly obese patients are thought to be at an increased risk for VTE. The aims of this study were twofold; first, to explore VTE rates in patients who have a body mass index (BMI) > 40 undergoing primary and revision total joint arthroplasty, and second, to investigate aspirin (ASA) efficacy and safety.
Methods: We identified all patients (n = 4,672) who had a BMI > 40 who underwent primary and revision total joint arthroplasty from 2016 to 2022 at a single academic tertiary care center. Patients were stratified by BMI groups: 40 to 44.9 (n = 3,462), 45 to 49.9 (n = 935), and 50+ (n = 275). The primary outcome was any VTE event within 90 days postoperatively. The secondary outcome consisted of wound complications within 90 days postoperatively.
Results: The total VTE rate was 0.4% (n = 21) and did not differ statistically between the BMI groups (0.4 versus 0.4 versus 0.7%, P = .669). The VTEs consisted of 6 deep venous thromboses (DVTs), 14 pulmonary embolisms, and one concomitant deep venous thrombosis and pulmonary embolism. The VTE rates were not statistically different between patients who received aspirin 325 mg 0.5% (n = 9), aspirin 81 mg 0.2% (n = 1), aspirin + anticoagulant (AC) 0.5% (n = 6), and AC alone 0.4% (n = 5) (P = .954). In addition, wound complications did not differ significantly between patients who received ASA 325 mg, ASA 81mg, ASA + AC, or AC alone (1.6 versus 1.0 versus 1.8 versus 1.1%, P = .351).
Conclusions: The use of aspirin 325 and 81 mg was found to have similar VTE rates as aspirin + ACs and ACs alone, with no significant increase in wound complications. In patients who have a BMI > 40, the use of aspirin is a safe option for VTE prophylaxis and should be prescribed in the context of the patient who has other risk factors for VTE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.arth.2024.05.053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial.
Circulation
September 2025
Division of Cardiology, Columbia University Irving Medical Center, New York, NY (S.A.P.).
Background: Limited treatment options exist for infrapopliteal disease in patients with chronic limb-threatening ischemia (CLTI), a condition associated with a high risk of limb loss. Interventional management of diseased infrapopliteal vessels with percutaneous transluminal angioplasty (PTA) is associated with high rates of restenosis and reintervention. In the LIFE-BTK trial, the drug-eluting resorbable scaffold (DRS) demonstrated superior 12-month efficacy compared with PTA in a selected CLTI population with predominantly noncomplex, mildly to moderately calcified lesions.
View Article and Find Full Text PDFChanging Utilization of Primary Anatomic and Reverse Shoulder Arthroplasty in a Single High-Volume Institution: A Retrospective Cohort Study.
Orthop Res Rev
September 2025
Department of Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, TX, USA.
Objective: The incidence of total shoulder arthroplasty (TSA) in the United States continues to climb as an aging yet active population increases demand for the procedure. Due to promising clinical results out of Europe, improvement in prosthesis design, and wider acceptance of reverse total shoulder arthroplasty (rTSA), this study was designed to evaluate how rTSA and anatomical TSA (aTSA) utilization, patient selection, and length of stay have changed at a single institution.
Methods: This was a retrospective cohort study of patients from one hospital system between 2017 and 2023.
Disparities in Diagnostic Utilization Patterns Between Heart Failure With Preserved Ejection Fraction (HFpEF) and Heart Failure With Reduced Ejection Fraction (HFrEF): A Nationwide Analysis.
Cureus
August 2025
Department of Health Sciences, University of Jamestown, Fargo, USA.
Background Heart failure (HF) is a leading cause of morbidity and hospitalization, encompassing distinct phenotypes: heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). Disparities in diagnostic imaging may contribute to underdiagnosis and unequal care. This study evaluates differences in combined diagnostic imaging utilization between HFpEF and HFrEF, focusing on social determinants of health (SDoH) and hospital region.
View Article and Find Full Text PDFLower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).
Diabetes Obes Metab
September 2025
Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Aims: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings.
Materials And Methods: Individuals initiating semaglutide 2.
[Why are we revising our primary knee arthroplasties? An evaluation of the causes for revision of primary knee arthroplasties over a five-year period (2018-2022)].
Acta Ortop Mex
September 2025
Departamento de Cirugía Ortopédica y Traumatología, Unidad de Cirugía de Rodilla, Hospital Clínico San Carlos. Madrid, España.
Introduction: the progressive increase in the volume of primary knee arthroplasty surgery is leading in parallel to an increase in revision surgeries, and this trend is expected to continue in the coming decades.
Material And Methods: a retrospective observational study with 203 interventions in 201 patients with knee arthroplasty revision surgery at our center between 2018-2022, including the variables age, sex, body mass index, primary implant, time until revision surgery, mechanical alignment of the primary implant, cause of revision, revision implant, and need for secondary revision.
Results: the average age of the patients was 73.